2 terminated. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Terminated 2 |
Follow Intercept Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Obeticholic Acid (OCA), Placebo - Liver Cirrhosis, Biliary | Phase 4 | Terminated | Intercept Pharmaceuticals | 22 | 2018-06-22 | 2022-09-06 |
| Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Obeticholic Acid (OCA), Placebo - Liver Cirrhosis, Biliary | Phase 4 | Terminated | Intercept Pharmaceuticals | 334 | 2014-12-26 | 2023-03-09 |
Fibrosis (2) · Liver Cirrhosis, Biliary (2)
obeticholic acid (2)
Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Estonia (2) · Germany (2) · Hungary (2) · Italy (2) · Lithuania (2) · Spain (2) · United States (2) · Austria (1) · Bulgaria (1) · Chile (1)
Erik Ness, MD (1) · Steven Shiff, M.D. (1)